John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.
John Crown, BCh, BAO, BSc, MD, MBA
Advertisement
Articles by John Crown, BCh, BAO, BSc, MD, MBA
John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
Advertisement
Latest Updated Articles
Dr. Crown on the Role of Eribulin Mesylate in TNBCPublished: September 17th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
5